市場調查報告書
商品編碼
1102190
真實世界證據(RWE)解決方案全球市場~2029,按組件(數據集/服務),應用程序(市場准入,腫瘤學,神經病學,上市後),用戶(製藥/醫療保健提供商)Real-world Evidence (RWE) Solutions Market by Component (Datasets, Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2029 |
在預測期內,真實世界證據 (RWE) 解決方案的市場規模預計將以 11.8% 的複合年增長率增長,到 2029 年達到 49 億美元。
醫療保健行業大數據的快速增長、從基於數量的護理向基於價值的護理轉變、對個性化醫療的日益關注等因素是推動該市場增長的主要因素。此外,新興市場、對端到端 RWE 服務的日益關注,以及可穿戴設備和人工智能在 RWE 中的日益普及,為進入者提供了巨大的增長機會。
本報告調查全球真實世界證據 (RWE) 解決方案市場,提供市場的定義和概述,分析市場增長的各種影響因素、法律和監管環境、市場規模的變化和預測、各種細分細分市場/地區/主要國家、競爭環境、主要公司概況等。
Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029
The RWE solutions market is expected to grow at a CAGR of 11.8% from 2022 to 2029 to reach $4.9 billion by 2029
Following a thorough primary and secondary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, opportunities, and challenges.
Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.
The RWE solutions market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users) and Geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyses their market shares at the global and regional levels.
Based on component, the datasets segment is expected to command the largest share of the global RWE solutions market in 2022 due to factors such as the rising dependence of outcome-based studies on real-world data, increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Based on application, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. The increasing investments by pharma and biopharma companies in R&D, increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE) are the factors contributing to the growth of this segment.
Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. The increasing importance of RWE studies in drug development &approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are the factors contributing to the growth of this segment.
An in-depth analysis of the geographical scenario of the RWE solutions market provides detailed qualitative and quantitative insights about the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global RWE solutions market in 2022, followed by Asia-Pacific and Europe. However, Asia-Pacific is slated to register the fastest growth rate. The growth of this regional market is driven by the growing demand for data defining the value and effectiveness of medicines, the increasing need for conducting real-world studies in drug R&D, and the rising government initiatives for promoting the use of real-world studies for regulatory decision-making.
Some of the key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Global RWE Solutions Market, by Component
(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)
Global RWE Solutions Market, by Application
(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)
Global RWE Solutions Market, by End User
(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)
Global RWE Solutions Market, by Geography